SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?
Zacks · 2d ago
Is Acadia Pharmaceuticals a Buy?
MotleyFool.com · 4d ago
Clovis Oncology: You Should Embrace Volatility To Enjoy Profitability
Seeking Alpha - Article · 05/29 17:22
Clovis Oncology (CLVS) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/29 17:13
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Business Wire · 05/28 13:00
Cancer treatment guidelines add new recommendations for Clovis' Rubraca
Seeking Alpha - Article · 05/28 12:41
Clovis Oncology Reports New Recommendations For Rubraca Tablets In Updated National Comprehensive Cancer Network Guideliness
Clovis Oncology, Inc. (NASDAQ:CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new recommendations for
Benzinga · 05/28 12:10
Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/28 10:06
Clovis Oncology Option Alert: Jul 17 $10 Calls at the Ask: 526 @ $0.401 vs 4747 OI; Ref=$6.46
Benzinga · 05/27 14:57
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Benzinga · 05/24 18:40
HC Wainwright & Co. Reiterates Buy on Clovis Oncology, Lowers Price Target to $29
HC Wainwright & Co. reiterates Clovis Oncology (NASDAQ:CLVS) with a Buy and lowers the price target from $33 to $29.
Benzinga · 05/22 10:55
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Business Wire · 05/21 21:10
Clovis Oncology Needs a Savior
GuruFocus.com · 05/21 19:24
SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to $4
SVB Leerink maintains Clovis Oncology (NASDAQ:CLVS) with a Underperform and lowers the price target from $5 to $4.
Benzinga · 05/20 10:45
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
8 Biotechs Tapping Secondary Markets for $3 Billion
GuruFocus.com · 05/19 23:53
Why Clovis Oncology's Stock Is Trading Lower Today
Benzinga · 05/19 20:09
Why Clovis Oncology's Stock Is Trading Lower Today
Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday.
Benzinga · 05/19 19:09
Seeing An Opportunity In Clovis Oncology
Seeking Alpha - Article · 05/19 17:05